Pregnant women with one or more high risk and women with two or more moderate risk of developing preeclampsia calcium carbonate pre-eclampsia prevention
Conditions
Interventions
1250 mg of calcium carbonate tablet, taking three times a day starting at the enrollment or at 12 weeks of gestation,1250 mg of calcium carbonate tablet, taking once daily
High-dose calcium carbonate,Standard dose calcium carbonate
Sponsors
None listed
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Those who have one or more high-risk or two or more moderate risks of developing pre-eclampsia High risk of developing pre-eclampsia was defined as a pregnant woman with multifetal gestation, chronic hypertension, type 1 or type 2 diabetes, renal disease, autoimmune disease (e.g., systemic lupus erythematosus and antiphospholipid syndrome), and a history of pre-eclampsia. Moderate risk was defined as women with nulliparity, obesity with body mass index more than 30 kg/m2, family history of pre-eclampsia, age 35 years or older, personal history factors (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, more than 10-year pregnancy interval)
Exclusion criteria
Exclusion criteria: Exclusion criteria were patients with a history of kidney or ureteric stone, parathyroid disorders, untreated nasal polyp, aspirin-induced bronchospasm, gastrointestinal or urinary hemorrhage, severe liver disease, hypercalcemia (serum corrected calcium level more than 10.5 mg/dL), allergic to aspirin or CaCO3, and other underlying diseases already receiving aspirin or calcium supplementation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of pre-eclampsia with severe features Until delivery Incidence | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of pre-eclampsia without severe features Until delivery Incidence,Incidence of gestational hypertension Until delivery Incidence,Gestational age at delivery until delivery gestational age (weeks),Neonatal outcome until discharge Apgar, birthweight, NICU admission and length of stay,Adverse event until delivery constipation, nausea and vomiting, PPH | — |
Countries
Thailand
Contacts
Public ContactPat Leelaamornvichet
Department of Obstetrics and Gynelocogy, Chonburi Hospital
Outcome results
None listed